The mediation of aryl ketone deuteration by [Ir(PPh3)3(cod)]+.BF4−

The usefulness of the hydrogen isotope exchange catalyst, [Ir(PPh₃)₃(cod)]⁺.BF₄^? (1), is explored. It appears that isotopic exchange mediated by 1 occurs via a series of complexes in which all three phosphine ligands are retained. The disadvantage of this system is that the catalytic intermediates are necessarily sterically hindered, with the result that the range of substrates for which the system is effective is small. Copyright © 2005 John Wiley & Sons, Ltd.     

Ligand effects upon deuterium exchange in arenes mediated by [Ir(PR3)2(cod)]+.BF4−

A series of complexes of general form [Ir(PR₃)₂(cod)]⁺ has been prepared and used, without isolation, to mediate deuteration of a range of model substrates. The data suggest that, with many substrates, basicity of the phosphine ligands bound to iridium is an important factor influencing substrate selectivity and the efficiency of deuteration. In addition, the spectrum of activity of iridium complexes bearing pure donor ligands is different in many cases to that of complexes where the ligands are known to be π‐acids. Copyright © 2003 John Wiley & Sons, Ltd.     

Catalyst stability as a factor in iridium‐mediated ortho‐deuteration

Crossover experiments show that iridium complexes such as Ir(cod)(Py)(PCy₃).PF₆ ( 1 ) and Ir(cod)(PPh₃)₂.BF₄ are inactivated after a comparatively short period during deuterium exchange reactions. This effect can be limited to some extent by optimizing the concentration at which exchange is performed, but altering physical parameters and adding labile ligands in an effort to stabilize reactive intermediates does not improve matters. Complexes of bidentate arsines and PN ligands and, in some cases, bidentate phosphines, exhibit better stability. Unexpectedly, following hydrogenolysis, 1 is able to mediate deuterium exchange from deuterium oxide into amides and N‐heterocycles at room temperature. Copyright © 2007 John Wiley & Sons, Ltd.     

Synthesis of C‐14‐labeled novel IKK inhibitor: 2‐[14C]‐N‐(6‐chloro‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐3‐pyridinecarboxamide

2‐[¹⁴C]‐N‐(6‐Chloro‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐3‐pyridinecarboxamide (9A , also referred to as [¹⁴C]‐PS‐1145) was synthesized from [¹⁴C]‐paraformaldehyde in five steps in an overall radiochemical yield of 15%. The key intermediate 1‐[¹⁴C]‐6‐chloro‐1,2,3,4‐tetrahydro‐β‐carboline was obtained by Pictet–Spengler cyclization of chlorotryptamine with [¹⁴C]‐paraformaldehyde. Similar reactions were conducted with tryptamine to address the generality of the methodology. Copyright © 2005 John Wiley & Sons, Ltd.     

Synthesis of C‐14 and C‐13, H‐2‐labeled IKK inhibitor: [14C] and [13C4,D3]‐N‐(6‐chloro‐7‐methoxy‐9H‐pyrido[3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide

[¹⁴C]‐N‐(6‐Chloro‐7‐methoxy‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide (5B ), an IKK inhibitor, was synthesized from [¹⁴C]‐barium carbonate in two steps in an overall radiochemical yield of 41%. The intermediate, [carboxyl‐¹⁴C]‐2‐methylnicotinic acid, was prepared by the lithiation and carbonation of 3‐bromo‐2‐methylpyridine. [¹³C₄,D₃]‐N‐(6‐chloro‐7‐methoxy‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide (5C ) was synthesized from [1,2,3,4‐¹³C₄]‐ethyl acetoacetate and [D₄]‐methanol in six steps in an overall yield of 2%. [¹³C₄]‐2‐methylnicotic acid, was prepared by condensation of [¹³C₄]‐ethyl 3‐aminocrotonate and acrolein, followed by hydrolysis with lithium hydroxide. Copyright © 2006 John Wiley & Sons, Ltd.     

Preparation of α‐labeled aldehydes by base‐catalyzed exchange reactions

A simple, efficient protocol for the preparation of α‐labeled aldehydes based on H/D exchange catalyzed by 4‐(N,N‐dimethylamino)pyridine or Et₃N is described. High chemical yields and ratios of isotope incorporation were obtained even when small amounts (～1 mmol) of aldehyde were used. Copyright © 2010 John Wiley & Sons, Ltd.     

A new synthesis of [26,28‐2H6]brassinolide and [26,28‐2H6]castasterone via an unusual methyl migration

Deuterium‐labelled brassinosteroids, namely [26,28‐²H₆]castasterone, 8 , and [26,28‐²H₆]brassinolide, 9 , were synthesized starting from 6,6‐ ethylenedioxy‐20‐formyl‐2α,3α‐isopropylidenedioxy‐5α‐pregnane, 1 , and 3‐[²H₃]methyl‐but‐1‐yne‐[4,4,4‐²H₃], 11 . Upon alkylating cleavage of the epoxide 6 with trimethylaluminium‐n‐butyllithium an unusual migration of a neighbouring [²H₃]methyl group takes place to afford deuteriation at positions 26 and 28. Copyright © 2002 John Wiley & Sons, Ltd.     

Synthesis of tracer labelled [11,12‐3H]‐β‐carotene

The synthesis of tracer labelled [11,12‐³H]‐β‐carotene is described. The procedure uses Wittig condensation of tracer labelled ³H‐retinal (retinal spiked with [11,12‐³H]‐retinal) with retinyl triphenylphosphonium bromide. The preparation of tracer labelled[³H]‐β‐carotene is suitable for studies involving bioavailability and bioconversion of β‐carotene to vitamin A. Copyright © 2003 John Wiley & Sons, Ltd.     

Synthesis of 5‐[4,5‐13C2]‐ and 5‐[1,5‐13C2]aminolevulinic acid

5‐[4,5‐¹³C₂]‐ and 5‐[1,5‐¹³C₂]Aminolevulinic acid (ALA) have been synthesized by the Gabriel condensation of potassium phthalimide with ethyl bromo[1,2‐¹³C₂]acetate (derived from [1,2‐¹³C₂]acetic acid) or ethyl bromo[2‐¹³C]‐acetate (derived from sodium [2‐¹³C]acetate), followed by conversion to the chloride, coupling reaction with 2‐ethoxycarbonylethylzinc iodide derived from ethyl 3‐iodopropionate or 2‐methoxy[¹³C]carbonylethylzinc iodide derived from methyl 3‐iodo[1‐¹³C]propionate (generated from potassium [¹³C]cyanide), and hydrolysis. Copyright © 2002 John Wiley & Sons, Ltd.     

Meta‐substituent effects on organoiridium‐catalyzed ortho‐hydrogen isotope exchange

Reports in the literature appear to differ on the effects of some C3 substituents on the relative efficiencies of isotope exchange in the nonidentical C2‐ and C6‐positions catalyzed by organoiridium complexes. Controlled experiments were conducted using a set of model substrates in attempts to clarify these effects. The results clearly showed that, in common with most previous findings, alkyl substituents at C3 reduced the rate of isotope incorporation into C2 relative to C6, as expected on steric grounds. In contrast, all substituents possessing electron lone pairs resulted in a lessening of the inhibition of C2‐vs‐C6 labeling or promoted C2 labeling to such a degree that it became faster than that at C6. NMR measurements on equimolar mixtures of active iridium complex with selected substrates revealed that the ratios of C2‐ and C6‐iridacycles present in solution correlated with the relative rates of ortho‐deuteration in the rate studies. The results of the two studies, taken together, suggest that conventional explanations for the origin of the positive meta‐effect may not be adequate for the present system. An alternative hypothesis is advanced. Copyright © 2009 John Wiley & Sons, Ltd.     

A route to the γ‐secretase inhibitor [2,3,4‐3H]BMS299897 via an α‐phenylselenide derivative

A method for the preparation of [2,3,4‐³H]BMS299897 has been developed. The methyl ester of BMS299897 was oxidized to its double bond derivative, via a phenyl selenide. The resulting double bond was reduced with tritium using Wilkinson's catalyst. The tritiated BMS299897 was isolated, after basic hydrolysis, with a specific activity of 1.6 TBq/mmol. Copyright © 2009 John Wiley & Sons, Ltd.     

Synthesis of Novel Oxazolo[4,5‐b]pyridine‐2‐one based 1,2,3‐triazoles as Glycogen Synthase Kinase‐3β Inhibitors with Anti‐inflammatory Potential

A novel series of oxazolo[4,5‐b]pyridine‐2‐one based 1,2,3‐triazoles has been synthesized by click chemistry approach and evaluated for in vitro GSK‐3β inhibitory activity. Compound 4g showed maximum inhibition with IC₅₀ value of 0.19 μ m . Keeping in view the effect of GSK‐3β inhibition on inflammation, compounds 4g , 4d , 4f , 4i , 4n and 4q exhibiting significant GSK‐3β inhibition were examined for in vivo anti‐inflammatory activity in rat paw edema model. The compounds 4g , 4d , 4f and 4i showed pronounced in vivo anti‐inflammatory activity (76.36, 74.54, 72.72 and 70.90%, respectively, after 5h post‐carrageenan administration) and were further found to inhibit the pro‐inflammatory mediators, viz. NO, TNF‐ α , IL‐1 β , and IL‐6 substantially in comparison with indomethacin, an anti‐inflammatory drug as well as SB216763, a GSK‐3 β inhibitor, reported to exert a similar effect. Histopathology studies confirmed the tolerance of gastric mucosa to these compounds.     

Synthesis of [2H]‐labelled phase‐I‐metabolites using 1‐[2H]‐pyridinium hydrochloride

Simultaneous O‐demethylation and hydrogen/deuterium exchange of aryl‐methyl‐ethers can be obtained using 1‐[²H]‐pyridinium hydrochloride as reagent at 220°C for 6 h. This reaction was applied to dextromethorphan and various non‐steroidal anti‐inflammatory drugs. Copyright © 2005 John Wiley & Sons, Ltd.     

Automated synthesis of 11C‐β‐hydroxybutyrate by enzymatic conversion of 11C‐acetoacetate using β‐hydroxybutyrate dehydrogenase

1‐[¹¹C]‐β‐hydroxybutyrate was produced by conversion from 1‐[¹¹C]‐acetoacetate using (D)‐β‐hydroxybutyrate dehydrogenase in the presence of nicotinamide adenine dinucleotide with purification by ion exchange column chromatography. Radiochemical yield at the end of the synthesis was 10% for a total synthesis time of 36 min. High‐performance liquid chromatography analysis showed ≤4% impurities, principally unconverted acetoacetate. Residual tetrahydrofuran (34±11 ppm) and ethanol (77±30 ppm) were well under the tolerable limits for human studies. Copyright © 2008 John Wiley & Sons, Ltd.     

Syntheses of stable‐isotope labeled [M+7] and [M+6] 2‐(methylamino)imidazole

Stable isotope‐labeled 2‐methylaminoimidazole (M+7 and M+6) was required as an intermediate in the synthesis of mass labeled drug candidates. These two isotopomers were synthesized with total yields of 24 and 36%, respectively. Labeled 2‐aminoimidazole (M+4) was prepared from labeled isothiourea (M+3) and 2‐aminoacetaldehyde dimethyl acetal (M+1 and M+2). The (M+1) version of 2‐aminoacetaldehyde dimethyl acetal was obtained in two steps starting with potassium [¹⁵N]phthalimide, while the (M+2) version was prepared from the reduction of diethoxyacetamide with LiAlD₄. Two different approaches for the preparation of 2‐methylaminoimidazole from aminoimidazole were explored. Attempts to prepare protected 2‐aminoimidazole to couple with CH₃I (M+4) to form the desired labeled 2‐methyl‐aminoimidazole failed. However, methylation was achieved by applying N‐formamidation followed by deutero‐reduction. These successful syntheses allowed us to selectively label with nitrogen, carbon or hydrogen isotopes at most of the positions of 2‐methylaminoimidazole. Copyright © 2002 John Wiley & Sons, Ltd.     

Synthesis and In‐Vitro Anti‐Hepatitis‐B Virus Activity of 6H‐[1]Benzothiopyrano[4,3‐b] quinolin‐10‐ols

A series of 9‐methoxy‐6H‐[1]benzothiopyrano[4,3‐b]quinolin‐10‐ols with a Mannich side chain were synthesized and evaluated for their anti‐Hepatitis B virus (HBV) activity in HepG2.2.15 cells. Some compounds showed significant anti‐HBV activity with IC₅₀ values less than 41 μM. Among them, compound 9b was the most effective anti‐HBV agent (IC₅₀ = 1.7 μM, SI = 60.3).     

Novel probes for imaging amyloid‐β: F‐18 and C‐11 labeling of 2‐(4‐aminostyryl)benzoxazole derivatives

2‐(4‐Methylaminostyryl)‐6‐(2‐[¹⁸F]fluoroethoxy)benzoxazole ([¹⁸F]BF‐168) was prepared and found to be a potential probe for imaging amyloid‐β. The precursor, a 6‐(2‐tosyloxyethoxy)benzoxazole derivative, was fluorinated with [¹⁸F]KF and Kryptofix 222 in acetonitrile, and the crude product purified by semi‐preparative HPLC to give [¹⁸F]BF‐168. The radiochemical purity was >95% and the maximum specific activity was 106 TBq/mmol at the end of synthesis. The synthesis time was 110 min from the end of bombardment. 2‐(4‐[N‐methyl‐¹¹C]methylaminostyryl)‐5‐fluorobenzoxazole ([¹¹C]BF‐145) was also prepared from 2‐(4‐aminostyryl)‐5‐fluorobenzoxazole, [¹¹C]MeI and 5 N NaOH in DMSO, and purified by semi‐preparative HPLC. The radiochemical purity was >95% and the specific activity was 40–70 TBq/mmol at the end of synthesis. The synthesis time was 45 min from the end of bombardment. Copyright © 2004 John Wiley & Sons, Ltd.     

Microwave‐assisted synthesis of (RS) methyl‐2‐([2′‐14C]4,6‐dimethoxypyrimidin‐2′‐yloxy)‐2‐phenyl [1‐14C]ethanoate

We report here a facile synthesis of (RS) methyl‐2‐([2′‐¹⁴C]4,6‐dimethoxypyrimidin‐2′‐yloxy)‐2‐phenyl [1‐¹⁴C]ethanoate under microwave irradiation. Copyright © 2006 John Wiley & Sons, Ltd.     

Synthesis of N‐(3‐[18F]Fluoropropyl)‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)nortropane ([18F]FP‐β‐CIT)

N‐(3‐[¹⁸F]fluoropropyl)‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)nortropane ([¹⁸F]FP‐β‐CIT) was synthesized in a two‐step reaction sequence. In the first reaction, 1‐bromo‐3‐(nitrobenzene‐4‐sulfonyloxy)‐propane was fluorinated with no‐carrier‐added fluorine‐18. The resulting product, 1‐bromo‐3‐[¹⁸F]‐fluoropropane, was distilled into a cooled reaction vessel containing 2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐nortropane, diisopropylethylamine and potassium iodide. After 30 min, the reaction mixture was subjected to a preparative HPLC purification. The product, [¹⁸F]FP‐β‐CIT, was isolated from the HPLC eluent with solid‐phase extraction and formulated to yield an isotonic, pyrogen‐free and sterile solution of [¹⁸F]FP‐β‐CIT. The overall decay‐corrected radiochemical yield was 25 ± 5%. Radiochemical purity was > 98% and the specific activity was 94 ± 50 GBq/µmol at the end of synthesis. Copyright © 2006 John Wiley & Sons, Ltd.